设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2023 年第 12 期 第 18 卷

香砂六君子汤加减对胃癌患者术后肠黏膜屏障及免疫状态的影响

Effects of modified Xiangsha Liujunzi decoction on intestinal mucosal barrier and immune status in patients with gastric cancer after surgery

作者:唐潇然1呼健1赵鹏飞2

英文作者:Tang Xiaoran1 Hu Jian1 Zhao Pengfei2

单位:1解放军总医院第六医学中心中医医学部,北京100048;2北京中医药大学东方医院肿瘤科,北京100078

英文单位:1Department of Traditional Chinese Medicine the Sixth Medical Center of PLA General Hospital Beijing 100048 China; 2Department of Oncology Dongfang Hospital Beijing University of Chinese Medicine Beijing 100078 China

关键词:胃癌;香砂六君子汤加减;肠黏膜屏障;免疫状态

英文关键词:Gastriccancer;ModifiedXiangshaLiujunzidecoction;Intestinalmucosalbarrier;Immunestatus

  • 摘要:
  • 目的  探究香砂六君子汤加减对胃癌患者术后肠黏膜屏障及免疫状态的影响。方法  选取2021年1月至2022年2月于解放军总医院诊治的胃癌患者100例,经筛查和排除后,最终纳入统计89例,其中对照组40例、观察组49例。2组患者术后均给予常规治疗,观察组在常规治疗基础上给予香砂六君子汤加减治疗,2组患者均连续治疗7 d。比较2组患者中医证候积分、肠黏膜屏障指标、胃激素水平、细胞免疫指标和体液免疫指标。结果  2组患者治疗后便秘、腹胀、腹痛、呃逆评分和D-乳酸、二胺氧化酶、CD+8水平均低于治疗前,且观察组低于对照组[(1.48±0.16)分比(1.90±0.22)分,(1.12±0.13)分比(1.72±0.20)分,(1.11±0.12)分比(1.58±0.17)分,(1.22±0.14)分比(1.65±0.18)分,(6.1±0.8)mg/L比(8.2±1.0)mg/L,(16.2±1.7)kU/L比(20.6±2.1)kU/L,(22.0±2.1)%比(25.3±2.6)%],差异均有统计学意义(均P<0.05)。2组患者治疗后胃动素、胃泌素、CD+3、CD+4、免疫球蛋白A、免疫球蛋白M、免疫球蛋白G水平均高于治疗前,且观察组高于对照组,差异均有统计学意义(均P<0.05)。结论  胃癌患者术后应用香砂六君子汤可修复肠黏膜屏障,增强机体免疫,改善胃激素水平。

  • Objective To investigate the effects of modified Xiangsha Liujunzi decoction on intestinal mucosal barrier and immune status in patients with gastric cancer after surgery. Methods From January 2021 to February 2022, 100 patients with gastric cancer diagnosed and treated in PLA General Hospital were selected. After screening and exclusion, 89 patients were finally included in the statistics, including 40 cases in the control group and 49 cases in the observation group. Patients were given routine treatment after surgery in the two groups, and the observation group was given modified Xiangsha Liujunzi decoction treatment on the basis of routine treatment. Patients were continuously treated for 7 d in the two groups. The traditional Chinese medicine syndrome scores, intestinal mucosal barrier indicators, gastric hormone levels, cellular immune indicators and humoral immune indicators of patients were compared between the two groups. Results  The scores of constipation, abdominal distension, abdominal pain and hiccup and the levels of D-lactic acid, diamine oxidase and CD+8 of patients after treatment were lower than those before treatment in the two groups, and the observation group was lower than the control group[(1.48±0.16) vs (1.90±0.22), (1.12±0.13) vs (1.72±0.20), (1.11±0.12) vs (1.58±0.17), (1.22±0.14) vs (1.65±0.18), (6.1±0.8)mg/L vs (8.2±1.0)mg/L, (16.2±1.7)kU/L vs (20.6±2.1)kU/L, (22.0±2.1)% vs (25.3±2.6)%](all P<0.05). The levels of motilin, gastrin, CD+3, CD+4, immunoglobulin A, immunoglobulin M and immunoglobulin G of patients after treatment were higher than those before treatment in the two groups, and the observation group was higher than the control group (all P<0.05). Conclusion Postoperative application of Xiangsha Liujunzi decoction in patients with gastric cancer can repair the intestinal mucosal barrier, enhance the body′s immunity, and improve the gastric hormones level.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭